Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.18 EUR | +0.31% | +0.46% | +3.21% |
May. 28 | FMC briefly burdened by research success in the fight against diabetes | DP |
May. 28 | FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Berenberg reaffirms its Buy rating | ZD |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The group shows a rather high level of debt in proportion to its EBITDA.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.21% | 12.47B | A- | ||
+25.52% | 88.99B | C+ | ||
-24.52% | 74.82B | B- | ||
-5.56% | 25.03B | C+ | ||
+4.31% | 17.88B | A- | ||
-14.25% | 16.43B | B | ||
+2.97% | 15.77B | A- | ||
+70.11% | 13.09B | C- | ||
+79.20% | 13.21B | C+ | ||
+40.44% | 12.9B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FME Stock
- Ratings Fresenius Medical Care AG